PolyPid Ltd
NASDAQ:PYPD
PolyPid Ltd
PolyPid Ltd. is a clinical stage biopharmaceutical company focusing on the development, manufacture, and commercialization of administered therapies to improve surgical outcomes. The firm focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
PolyPid Ltd. is a clinical stage biopharmaceutical company focusing on the development, manufacture, and commercialization of administered therapies to improve surgical outcomes. The firm focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
Regulatory Progress: PolyPid completed its SHIELD II Phase III trial with positive results and expects to begin a rolling NDA submission for D-PLEX100 by the end of Q1 2026, supported by FDA feedback.
Commercial Partnerships: The company is in advanced discussions with U.S. commercial partners, aiming for organizations with strong hospital-based and surgical presence.
Financial Position: PolyPid ended 2025 with $12.9 million in cash; post quarter-end, warrant exercises added $3.7 million. Management expects cash to fund operations into the second half of 2026.
Expenses & Loss: Net loss for Q4 2025 was $8.5 million ($0.41/share) and for the full year was $34.2 million ($2.09/share), reflecting increased R&D and commercial preparation.
Pipeline Expansion: The company is advancing a GLP-1 receptor agonist program for metabolic disease using its next-generation Kynatrix technology, with more data expected around mid-2026.
Leadership Update: Brooke Story was appointed Chairman of the Board, bringing deep medtech experience as PolyPid prepares for commercialization.
